Table 2.
Pharmaceutical expenditure by type of antineoplastic drug in the period 2010–2019 in the clinical trial setting.
| Study Years | Expenditures of Antineoplastic Drugs | |
|---|---|---|
| Intravenous | Oral | |
| 2010 | EUR 2,457,850 | NR |
| 2011 | EUR 1,700,250 | NR |
| 2012 | EUR 2,203,633 | NR |
| 2013 | EUR 3,331,912 | EUR 1,845,309 |
| 2014 | EUR 4,636,490 | EUR 2,022,064 |
| 2015 | EUR 4,120,596 | EUR 2,876,494 |
| 2016 | EUR 6,220,320 | EUR 3,545,183 |
| 2017 | EUR 12,675,915 | EUR 6,086,139 |
| 2018 | EUR 17,844,749 | EUR 8,166,853 |
| 2019 | EUR 17,074,664 | EUR 10,497,663 |
| Total | EUR 72,266,379 | EUR 35,039,705 |
| Overall | EUR 107,306,084 | |
NR: not registered.